An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma.
Age Factors
Aged
Databases, Genetic
Female
Head and Neck Neoplasms
/ genetics
Humans
Immunity, Cellular
Male
Middle Aged
Mutation
Neoplasm Staging
Nomograms
Prognosis
Proportional Hazards Models
RNA, Long Noncoding
/ immunology
ROC Curve
Sex Factors
Squamous Cell Carcinoma of Head and Neck
/ genetics
Survival Analysis
Transcriptome
head and neck squamous cell carcinoma
immune
lncRNA
tumor microenvironment
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
04
01
2021
received:
17
08
2020
accepted:
05
01
2021
pubmed:
5
3
2021
medline:
20
7
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
In this study, we developed a long noncoding RNA (lncRNA)-based prognostic signature for stratification of patients with head a nd neck squamous cell carcinoma (HNSCC). In total, 493 HNSCC samples obtained from the Cancer Genome Atlas database were divided into training and testing cohorts (3:2 ratio). We identified 3913 immune-related lncRNAs in the HNSCC training cohort by Pearson correlation analysis; only seven were independently associated with overall survival and were used to develop an immune-related lncRNA prognostic signature (IRLPS) grouping of HNSCC patients into high- and low-IRLPS subgroups. Univariate and multivariate Cox analyses revealed that low-IRLPS patients had a better prognosis in all the cohorts, which was retained after stratification by sex, grade, and HPV status. Although the TNM stage was also an independent prognostic factor, the IRLPS had a better discriminability with higher AUC at the 3- and 5-year follow-ups in all cohorts. Low-IRLPS samples had more immune cell infiltration and were enriched in immune-related pathways, while high- IRLPS samples were enriched in metabolic pathways. A nomogram constructed including age, TNM stage, and IRLPS showed good calibration. Thus, IRLPS improves the prognostic prediction and also distinguishes different tumor microenvironment (TME) in HNSCC patients.
Identifiants
pubmed: 33660378
doi: 10.1002/cam4.3756
pmc: PMC7982618
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2268-2285Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Clin Cancer Res. 2021 Jan 1;27(1):330-341
pubmed: 33097495
Aging (Albany NY). 2020 Jan 12;12(1):767-783
pubmed: 31927533
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Cancer Immunol Immunother. 2019 Mar;68(3):433-442
pubmed: 30564892
Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3837-3841
pubmed: 28975982
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Front Oncol. 2020 Jan 31;10:48
pubmed: 32083005
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5086-95
pubmed: 25385645
Theranostics. 2018 Nov 10;8(20):5676-5689
pubmed: 30555573
Mol Cancer Ther. 2016 Oct;15(10):2475-2485
pubmed: 27466356
Sci Rep. 2020 Oct 6;10(1):16634
pubmed: 33024167
J Clin Invest. 2015 Feb;125(2):739-51
pubmed: 25562322
Front Oncol. 2019 Dec 04;9:1285
pubmed: 31867268
J Cancer. 2020 Apr 6;11(13):3858-3870
pubmed: 32328190
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Radiother Oncol. 2020 Jun;147:186-194
pubmed: 32413532
RNA Biol. 2012 Jun;9(6):703-19
pubmed: 22664915
Biomed Res Int. 2018 Mar 6;2018:7929104
pubmed: 29693014
J Immunol. 2000 Mar 15;164(6):3095-101
pubmed: 10706699
Oral Oncol. 2009 Oct;45(10):e167-74
pubmed: 19576838
Front Oncol. 2020 Sep 29;10:594224
pubmed: 33134183
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Res. 2019 Sep 15;79(18):4612-4626
pubmed: 31331909
J Hematol Oncol. 2013 May 31;6:37
pubmed: 23725405
Med Sci Monit. 2019 Jun 16;25:4485-4494
pubmed: 31203306
J Proteomics. 2011 Apr 1;74(4):558-66
pubmed: 21262401
Clin Epigenetics. 2017 Aug 24;9:88
pubmed: 28852427
Front Oncol. 2020 Mar 20;10:372
pubmed: 32266149
Aging (Albany NY). 2020 May 26;12(10):9188-9204
pubmed: 32453707
J Natl Cancer Inst. 2015 Feb 03;107(3):
pubmed: 25650315
Cancers (Basel). 2019 Jan 03;11(1):
pubmed: 30609853
Int J Mol Sci. 2018 Feb 28;19(3):
pubmed: 29495592
Cell Mol Neurobiol. 2021 Mar;41(2):365-375
pubmed: 32410107
Oncoimmunology. 2019 Jan 10;8(3):1535293
pubmed: 30723574
Sci Rep. 2020 Apr 14;10(1):6395
pubmed: 32286381
Can J Gastroenterol Hepatol. 2018 Oct 16;2018:5804376
pubmed: 30410872
Aging (Albany NY). 2020 May 23;12(10):9868-9881
pubmed: 32445554
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Med Genomics. 2020 Mar 30;13(1):57
pubmed: 32228580
Cancer Cell. 2015 Oct 12;28(4):529-540
pubmed: 26461095
Cancer Med. 2018 Dec;7(12):6219-6233
pubmed: 30378276
J Exp Clin Cancer Res. 2016 Sep 26;35(1):151
pubmed: 27669890
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Biomed Pharmacother. 2017 Jan;85:355-361
pubmed: 27890432
Brief Bioinform. 2020 May 08;:
pubmed: 32382761